These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 31977)

  • 1. Proceedings of the 4th Conference on Immune Modulation and Control of Neoplasia by Adjuvant Therapy. Division of Cancer Cause and Prevention, National Cancer Institute.
    Cancer Treat Rep; 1978 Nov; 62(11):1611-998. PubMed ID: 31977
    [No Abstract]   [Full Text] [Related]  

  • 2. The NCI preclinical screen of biological response modifiers.
    Talmadge JE; Fidler IJ; Oldham RK
    Behring Inst Mitt; 1984 May; (74):189-94. PubMed ID: 6206841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proceedings of the National Cancer Institute Conference on cis-platinum and testicular cancer, September 21-22, 1978, Washington, DC.
    Cancer Treat Rep; 1979; 63(9-10):1431-699. PubMed ID: 40695
    [No Abstract]   [Full Text] [Related]  

  • 4. Introduction to the 4th National Conference on Genomics and Public Health.
    McBride CM; Bowen SM; Shully SD; Khoury MJ
    Public Health Genomics; 2012; 15(3-4):117. PubMed ID: 22488452
    [No Abstract]   [Full Text] [Related]  

  • 5. Immunotherapy biomarkers 2016: overcoming the barriers.
    Gulley JL; Berzofsky JA; Butler MO; Cesano A; Fox BA; Gnjatic S; Janetzki S; Kalavar S; Karanikas V; Khleif SN; Kirsch I; Lee PP; Maccalli C; Maecker H; Schlom J; Seliger B; Siebert J; Stroncek DF; Thurin M; Yuan J; Butterfield LH
    J Immunother Cancer; 2017 Mar; 5(1):29. PubMed ID: 28653584
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Updates of adjuvant therapy in pancreatic cancer: where are we and where are we going? Highlights from the "2010 ASCO Annual Meeting". Chicago, IL, USA. June 4-8, 2010.
    Li J; Merl MY; Chabot J; Saif MW
    JOP; 2010 Jul; 11(4):310-2. PubMed ID: 20601799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Business barriers slowing the pace of cancer immunotherapy research and development.
    Tuma RS
    J Natl Cancer Inst; 2007 Nov; 99(21):1570-3. PubMed ID: 17971521
    [No Abstract]   [Full Text] [Related]  

  • 8. [Mammography. A conference on screening for carcinoma of the breast held by the National Institute of Health and the National Cancer Institute (author's transl)].
    Rofo; 1978 Sep; 129(3):368-70. PubMed ID: 28999
    [No Abstract]   [Full Text] [Related]  

  • 9. Use of adjuvants for immunotherapy.
    Circelli L; Tornesello M; Buonaguro FM; Buonaguro L
    Hum Vaccin Immunother; 2017 Aug; 13(8):1774-1777. PubMed ID: 28604160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Symposium on surgical treatment of morbid obesity. Proceedings of a consensus conference sponsored by the National Institute of Arthritis, Metabolism, and Digestive Diseases of the National Institutes of Health; held in December 1978 at Bethesda, Maryland.
    Am J Clin Nutr; 1980 Feb; 33(2 Suppl):353-530. PubMed ID: 6101932
    [No Abstract]   [Full Text] [Related]  

  • 11. Proceedings: European Organization for Research on Treatment of Cancer: origin, organization, and current activities.
    van Bekkum DW
    Natl Cancer Inst Monogr; 1974 Feb; 40():83-90. PubMed ID: 4150493
    [No Abstract]   [Full Text] [Related]  

  • 12. Adjuvant immunotherapy for cancer: both dendritic cell-priming and check-point inhibitor blockade are required for immunotherapy.
    Seya T; Takeda Y; Takashima K; Yoshida S; Azuma M; Matsumoto M
    Proc Jpn Acad Ser B Phys Biol Sci; 2018; 94(3):153-160. PubMed ID: 29526974
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical immunotherapy studies in the Surgery Branch of the U.S. National Cancer Institute: brief review.
    Rosenberg SA
    Cancer Treat Rev; 1989 Jun; 16 Suppl A():115-21. PubMed ID: 2670208
    [No Abstract]   [Full Text] [Related]  

  • 14. National Eye Institute--Melanoma Conference.
    Albert DM
    Am J Ophthalmol; 1979 Mar; 87(3):422-5. PubMed ID: 35004
    [No Abstract]   [Full Text] [Related]  

  • 15. Proceedings of the National Conference on Clinical Trials Methodology.
    Clin Pharmacol Ther; 1979 May; 25(5 Pt 2):629-766. PubMed ID: 35299
    [No Abstract]   [Full Text] [Related]  

  • 16. CpG oligodeoxynucleotides for immune stimulation in cancer immunotherapy.
    Jahrsdörfer B; Weiner GJ
    Curr Opin Investig Drugs; 2003 Jun; 4(6):686-90. PubMed ID: 12901226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. C.R.O.S. conference on combined modalities chemotherapy/radiotherapy. Hilton Head Island, South Carolina, November 15--18, 1978.
    Carter SK
    Cancer Chemother Pharmacol; 1979; 2(2):139-42. PubMed ID: 43777
    [No Abstract]   [Full Text] [Related]  

  • 18. [Basic background for adjuvant immunotherapy].
    Seya T
    Nihon Rinsho; 2012 Dec; 70(12):2059-65. PubMed ID: 23259375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reports from the Workshop on the Use of Steroids as Carriers of Cytotoxic Agents in Breast Cancer: Cancer Therapy Evaluation Program, Division of Cancer Treatment, National Cancer Institute.
    Cancer Treat Rep; 1978 Aug; 62(8):1239. PubMed ID: 28830
    [No Abstract]   [Full Text] [Related]  

  • 20. Highlights of the 31st annual meeting of the Society for Immunotherapy of Cancer (SITC), 2016.
    Gulley JL; Repasky EA; Wood LS; Butterfield LH
    J Immunother Cancer; 2017 Jul; 5(1):55. PubMed ID: 28716068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.